Pfizer Global Medical Grants (GMG) – Now LIVE!

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

 I would like to share a new RFP that may be of interest to you. This RFP is focused on supporting independent research initiatives.

 If you have any questions about this RFP or the grant application process, please contact my colleague, Jessica Romano, at [email protected].


 

Grant 1: 2022/2023 Global Cachexia ASPIRE

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

 

Date RFP Issued: September 20, 2022

Geographic Scope: Global

Clinical Area: Cachexia

Link to full RFP: 2022/2023 Global Cachexia ASPIRE

Application Due Date: January 5, 2023

Specific Area of Interest: The intent of this RFP is to support research projects in the following categories:

Evidence generation in Understanding Cachexia/Unintentional Weight Loss in Cancer or Heart Failure
Role of GDF-15/GFRAL Pathway in Disease
GDF-15/GFRAL Biology
Natural History (longitudinal) studies specifically related to cachexia/weight loss and/or heart failure


 

Grant 2: Engaging the Patient Community in Research and Publications

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to help improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s areas of interest. Consistent with Pfizer’s commitment to putting patients first, we are proud to collaborate with the Stanford Medicine AIM lab to release this RFP to support patient-powered research.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

 

Date RFP Issued: October 20, 2022

Geographic Scope: United States, Canada and Europe

Clinical Area: Infectious disease, drug resistant infections, Oncology and Internal Medicine

Link to full RFP: Engaging the Patient Community in Research and Publications

Application Due Date: December 8, 2022

Specific Area of Interest: Through this RFP, we intend to provide grants to strengthen the capabilities of the patient community by providing mentorship and training on how to conduct patient-partnered research with the goal to facilitate increased opportunities for collaboration between patients and academic-research communities.

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article